Tirzepatide 40mg

Tirzepatide (40 mg) is a synthetic lipidated peptide composed of 39 amino acids with a C20 fatty diacid moiety, produced through controlled laboratory synthesis for metabolic and endocrine research. The tirzepatide peptide has a molecular weight of approximately 4.8 kDa and is supplied to support experimental investigations in regulated laboratory settings. Researchers who order tirzepatide peptide for advanced studies often select this larger vial size for extended or repeated experimental protocols.

The peptide is supplied as a high-purity (≥98%) lyophilized powder in a sealed research-grade vial, supporting structural stability, storage consistency, and precise reconstitution. Its standardized format allows preparation of accurate concentrations for in vitro and preclinical research use.

In laboratory settings, tirzepatide has been studied for its role in metabolic regulation, including glucose-related processes and energy balance. Current investigations focus on the behavior of functional peptides within biological systems, without implying clinical or therapeutic applications.

• High-purity tirzepatide peptide suitable for reproducible laboratory research
• Documented purity and identity testing for research reliability
• Studied in experimental models of metabolic signaling and glucose regulation
• Suitable for in vitro and preclinical experimental systems
• Stable formulation when stored under recommended laboratory conditions
• Compatible with standard sterile reconstitution and handling techniques
• For laboratory research use only.

Tirzepatide is being researched for its effects on metabolic signaling and energy regulation under controlled laboratory conditions. Experimental models examine its interaction with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor systems and related influences on insulin activity and glucose handling.

Research applications focus on interactions between the metabolic and endocrine systems, particularly processes associated with nutrient responses and energy balance. These studies are designed to generate measurable laboratory data rather than therapeutic conclusions.

In laboratory studies, the tirzepatide peptide has been evaluated using nanomolar to micromolar concentrations in cell-based assays. Preclinical research models may apply weight-adjusted dosing protocols to observe biological responses under controlled experimental conditions.

Reported observations focus on laboratory-measured changes in metabolic markers, insulin-related activity, and glucose utilization. All findings are study-specific and reported as experimental data points.

All dosing information is provided solely to support research methodology and experimental reproducibility and does not represent guidance for human or veterinary use.

Store tirzepatide peptide in its lyophilized form at –20 °C or below, protected from light and moisture. Reconstituted solutions should be prepared using sterile technique, stored at 2–8 °C, and used within 72 hours unless stability data indicate otherwise. Avoid repeated freeze–thaw cycles to preserve peptide integrity. Follow standard laboratory safety procedures during handling. 

Laboratories that buy tirzepatide peptide should maintain appropriate documentation and handling protocols consistent with institutional research guidelines.

References

https://www.pnas.org/doi/10.1073/pnas.2116506119

https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9149770/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9396640/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.